Helus Pharma Inc.

As of June 30, 2026, Helus Pharma Inc. carries a market capitalization of 409.71M, placing it among publicly traded companies globally. Its enterprise value stands at 243.35M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Helus Pharma Inc.'s next confirmed earnings release is scheduled for November 16, 2026.

As of June 30, 2026, Helus Pharma Inc. has 61.98M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Helus Pharma Inc. maintains a current ratio of 10.97, meaning it holds 11.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Helus Pharma Inc. posted a negative return on equity (ROE) of -96.38, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -82.40, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 75.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Helus Pharma Inc.'s stock has gained approximately 80.72% over the past 52 weeks. The 50-day moving average sits at 12.12, while the 200-day moving average is 7.63.

Over the twelve months ended June 30, 2026, Helus Pharma Inc. generated - - in revenue and converted that into -168.18M in net income, yielding earnings per share of -3.97. EBITDA reached -164.04M, while operating income came in at -164.15M.

These figures are as of June 30, 2026. Total book value stands at 242.09M, with working capital of 175.13M providing operational flexibility.

Helus Pharma Inc. produced -138.31M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.43M in capital expenditures, free cash flow totaled -139.75M - equivalent to -3.30 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -49.94: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -45.24, meaning Helus Pharma Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Helus Pharma Inc.'s most recent stock split took place on September 19, 2024 with a 38:1 split ratio.

As of June 30, 2026, Helus Pharma Inc. has an Altman Z-Score of 9.10, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.